The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review

Abstract Background Monoclonal antibodies (mAbs) approved for use as add-on therapy in patients with severe asthma target the underlying pathogenesis of asthma. Main body Omalizumab binds immunoglobulin E (IgE), thereby inhibiting its interaction with the high-affinity IgE receptor and reducing the...

Full description

Bibliographic Details
Main Authors: Andrea Matucci, Alessandra Vultaggio, Romano Danesi
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Respiratory Research
Subjects:
Eosinophil
Mepolizumab
Monoclonal antibodies
Omalizumab
Reslizumab
Severe asthma
Online Access:http://link.springer.com/article/10.1186/s12931-018-0859-z

Internet

http://link.springer.com/article/10.1186/s12931-018-0859-z

Similar Items